NTRK1 and rheumatoid arthritis: Nowadays, anti-VEGF/VEGFR2 therapies seem to be beneficial for animal models of RA and also have a great therapeutic promise for RA (Le and Kwon, 2021), such as Avastin (Bevacizumab, a VEGF humanized monoclonal antibody) (Wang et al., 2013) and Sorafenib (a proangiogenic receptor tyrosine kinase inhibitor, which mainly suppresses the expression of VEGFR2) (Wang et al., 2018).